Suraksha Diagnostic Q2 FY27 PAT Climbs 69%, EBITDA Up 45% on Higher Revenues and Patient Volume
The diagnostic chain reported ₹1,893.09 million total income in H1 FY27, a 24% increase year-on-year, driven by expanding network and increased test volumes
Suraksha Diagnostic Limited announced strong unaudited financial results for the quarter and half year ended September 30, 2026, with profit after tax up 69% in Q2 FY27 and EBITDA increasing by 45%. Total income rose 24% for H1 FY27 to ₹1893.09 million, reflecting growth in patient volumes and test revenue.
Suraksha Diagnostic Limited
General / Other
Suraksha Diagnostic Limited reported substantial financial growth in the quarter ended September 30, 2026, with profit after tax rising 69% year-on-year to ₹149.50 million and EBITDA growing 45% to ₹363.17 million in Q2 FY27, supported by a 24% increase in total income for H1 FY27 to ₹1,893.09 million.
The company's earnings before interest, taxes, depreciation, and amortization (EBITDA) margins improved to 36.7% in Q2 FY27 from 31.7% in Q2 FY26, reflecting operational efficiency.
Total tests conducted increased by 5% year-on-year to 2.32 million in Q2 FY27, while total patients rose 12% to 0.42 million in the same period.
Average revenue per test grew 19% year-on-year to ₹427, and average revenue per patient increased 13% to ₹2,348, indicating higher service realization.
Suraksha Diagnostic expanded its network by opening five new centres during the quarter, including two hub centres and three spoke centres, strengthening its presence in West Bengal and entering new markets.
Suraksha Genomics remains a growth focus area, positioned for future contributions to the business as part of its diversified healthcare offerings.
Highlights
- Q2 FY27 Profit After Tax: ₹149.50 million, up 69% year-on-year
- Q2 FY27 EBITDA: ₹363.17 million, increased 45% year-on-year
- H1 FY27 Total Income: ₹1,893.09 million, a 24% rise over previous year
- Q2 FY27 Total Tests: 2.32 million, up 5% year-on-year
- Q2 FY27 Total Patients: 0.42 million, up 12% year-on-year
- Opened five new diagnostic centres in Q2 FY27 to expand regional footprint
Key Data Snapshot
Key details
- Suraksha Diagnostic's total income for Q2 FY27 increased by 26% year-on-year to ₹1,005.75 million, contributing to H1 FY27 income growth of 24% to ₹1,893.09 million.
- EBITDA rose 45% year-on-year in Q2 FY27 to ₹363.17 million, with H1 FY27 EBITDA reaching ₹678.47 million, a 37% increase over the prior year.
- Profit after tax (PAT) jumped 69% in Q2 FY27 to ₹149.50 million and 54% for H1 FY27 to ₹277.96 million.
- Test volumes increased 5% in Q2 FY27 with 2.32 million tests conducted and 12% patient growth to 0.42 million.
- The company's network expansion included five new centres in the quarter, aligning with its strategy of regional clustering.
Strategic context
- Suraksha Diagnostic is the largest integrated diagnostic chain in East India, operating across West Bengal, Bihar, Assam, and Jharkhand.
- The company aims to strengthen contributions from recently commissioned centres and pursue disciplined expansion into new markets.
- Suraksha Genomics is positioned as a future growth engine, focusing on building presence in the genomics testing segment.
- Centres hold accreditations from the College of American Pathologists, NABL, and NABH ensuring quality and standards in diagnostics.
Management commentary
- Ms. Ritu Mittal, Joint Managing Director & CEO, stated the company is focused on sustainable growth through existing network and expansion into newer markets.
- She highlighted that newly opened centres are progressively maturing and contributing to overall business growth.
- The management continues to prioritize strong operational performance and leveraging genomics as a meaningful contributor in coming years.
Highlights
- Q2 FY27 Profit After Tax: ₹149.50 million, up 69% year-on-year
- Q2 FY27 EBITDA: ₹363.17 million, increased 45% year-on-year
- H1 FY27 Total Income: ₹1,893.09 million, a 24% rise over previous year
- Q2 FY27 Total Tests: 2.32 million, up 5% year-on-year
- Q2 FY27 Total Patients: 0.42 million, up 12% year-on-year
- Opened five new diagnostic centres in Q2 FY27 to expand regional footprint
Disclosures
- SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015
- BSE Circular No. 20230714-34 dated 14 July 2023
- NSE Circular No. NSE/CML/2023/57 dated 14 July 2023
More News on General / Other
View allLatest corporate announcements and market updates in General / Other.
Sobhagya Mercantile Ltd. Sets Extraordinary General Meeting for December 11, 2026, via Video Conferencing
Sobhagya Mercantile Limited has issued a public notice convening an Extraordinary General Meeting (EGM) scheduled for December 11, 2026, at 11:30 A.M. IST. The meeting will be conducted through video conferencing and other audio-visual means, with e-voting facilities provided to shareholders.
Read Full StoryAPL Apollo Tubes Denies Promoter Stake Sale Rumors Following Speculative News
APL Apollo Tubes Limited issued a clarification on November 20, 2026, denying any knowledge or communication regarding a proposed sale of promoter family shares amid speculative media reports.
Read Full StoryIndusInd Bank Conducts November 2026 Investor and Analyst Meetings in Chennai with Leading Asset Managers
On November 19, 2026, IndusInd Bank Limited conducted analyst and institutional investor meetings in Chennai, involving prominent asset management companies such as Franklin Templeton, Bandhan AMC, Axis AMC, and Motilal Oswal AMC. The bank clarified no unpublished price sensitive information was shared during these discussions.
Read Full Story